Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 11;18(1):75.
doi: 10.1186/s13023-023-02678-6.

A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases

Affiliations

A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases

Ania Korsunska et al. Orphanet J Rare Dis. .

Abstract

Background: There are approximately 10,000 rare diseases that affect around 30,000,000 individuals in the U.S.A., most of which do not have an FDA-approved treatment. This fact highlights the failure of traditional research approaches to overcome the unique challenges of developing rare disease treatments. The Castleman Disease Collaborative Network was founded in 2012 to advance research and treatments for Castleman disease, a rare and deadly disease that involves the immune system attacking the body's vital organs for an unknown cause. It has spearheaded a novel strategy for advancing biomedical research, the Collaborative Network Approach. This approach consists of eight steps, one of which is to identify and prioritize high-impact research questions through crowdsourcing ideas from the entire community of stakeholders: patients, loved ones, physicians, and researchers. Rather than hoping that the right researcher will apply for the right research project at the right time, crowdsourcing high-priority research projects into a research strategy ensures that the most high-impact, patient-centered studies are prioritized. The Castleman Disease Collaborative Network launched an initiative in 2021 to systematically generate this list of community-directed studies to focus Castleman disease research efforts.

Results: The Castleman Disease Collaborative Network was able to successfully create a patient-centered research agenda through engaging the entire community of stakeholders. The community contributed important questions about Castleman disease, which were prioritized and reviewed by our Scientific Advisory Board, and the result was a finalized list of studies that address these prioritized questions. We were also able to generate a best practices list which can serve as a model that can be utilized for other rare diseases.

Conclusion: Creating a patient-centered research agenda through crowdsourcing research ideas from the community is one of the most important ways that the Castleman Disease Collaborative Network operationalizes its commitment to keeping patients at the center of research and we hope that by sharing these insights we can assist other rare disease organizations to pursue a patient-centric approach.

Keywords: Castleman disease; Collaborative network; Crowdsourcing; Patient-centered research agenda; Rare disease.

PubMed Disclaimer

Conflict of interest statement

Not applicable.

Figures

Fig. 1
Fig. 1
The traditional model of an organization supporting research
Fig. 2
Fig. 2
CDCN’s eight step Collaborative Network Approach [4]
Fig. 3
Fig. 3
CDCN’s five-phase approach to crowdsourcing research ideas
Fig. 4
Fig. 4
Timeline of the crowdsourcing process
Fig. 5
Fig. 5
Ten broad research categories identified through idea synthesis
Fig. 6
Fig. 6
Grading guidance given to members of the Scientific Advisory Board (SAB)
Fig. 7
Fig. 7
Participation among the follow up survey participants
Fig. 8
Fig. 8
Ranking of the clarity and effectiveness of communication around the initiative
Fig. 9
Fig. 9
Participation methods among patients and loved ones
Fig. 10
Fig. 10
Participation methods among physicians and researchers

Similar articles

Cited by

  • Rare Disease Drug Repurposing.
    Nijim S, Korsunska A, Zinski J, Bolden SE, Zuccato M, Repasky M, Fajgenbaum DC. Nijim S, et al. JAMA Netw Open. 2025 May 1;8(5):e258330. doi: 10.1001/jamanetworkopen.2025.8330. JAMA Netw Open. 2025. PMID: 40323602 Free PMC article.

References

    1. Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020 Feb;19(2):77–8. - PMC - PubMed
    1. Orphan Drug Act [Internet]. 96 STAT. 2049, 97–414 Jan 4, 1983. Available from: https://www.fda.gov/media/99546/download
    1. Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases–the view from the National Center for Advancing Translational Sciences–Office of Rare Diseases Research. Orphanet J Rare Dis. 2018 Dec;13:1–8. - PMC - PubMed
    1. Zuccato M, Shilling D, Fajgenbaum DC. The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. MacKenzie A, Groft S, Justice M, van Karnebeek C, editors. Emerging Topics in Life Sciences. 2019 Mar 29;3(1):97–105. - PubMed
    1. Mickute G, Staley K, Delaney H, Gardiner O, Hunter A, Keen R, et al. Rare musculoskeletal diseases in adults: a research priority setting partnership with the James Lind Alliance. Orphanet J Rare Dis. 2020 May;19(1):117. - PMC - PubMed

Publication types

LinkOut - more resources